MétaCan
Menu
Retour à la cohorte
Enregistrement W4410982365 · doi:10.1016/j.waojou.2025.101066

Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR)

2025· article· en· W4410982365 sur OpenAlex

Pourquoi ce travail est dans la base

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

affAu moins un auteur déclare une institution canadienne dans l'instantané OpenAlex épinglé.
fundUn bailleur canadien est enregistré sur le travail.

Notice bibliographique

RevueWorld Allergy Organization Journal · 2025
Typearticle
Langueen
DomaineMedicine
ThématiqueAsthma and respiratory diseases
Établissements canadiensVancouver General HospitalKingston General HospitalUniversity of AlbertaUniversité LavalVancouver Coastal Health Research InstituteEmissions Reduction AlbertaVancouver Coastal HealthUniversité de SherbrookeUniversity of TorontoQueen's UniversityVancouver Hospital and Health Sciences CentreUniversity of British Columbia
Organismes subventionnairesFaculty of Medicine and Health, University of SydneyDaiichi Sankyo EuropeMedical Research CouncilCanadian Institutes of Health ResearchSanofi GenzymeDirectorate for Biological SciencesNovartis Pharmaceuticals UK LimitedNational Jewish HealthHumanitas Research HospitalLung Health FoundationGrifolsOrient EuropharmaKing Fahad Medical CityBritish Columbia Lung AssociationTeva Pharmaceutical IndustriesAlfaisal UniversityCentro de Investigação em Tecnologias e Serviços de SaúdeGenentechUniversity of AlbertaStiftung Universitätsmedizin EssenShirePontificia Universidad JaverianaUniversidad del RosarioVancouver Coastal Health Research InstituteKuwait Foundation for the Advancement of SciencesUniversidade do PortoAstraZeneca AustraliaNovo NordiskSwedish Orphan BiovitrumUniversitetet i BergenQueen's UniversityLunds UniversitetQueen's University BelfastShanghai Educational Development FoundationTaichung Veterans General HospitalAsthma AustraliaBispebjerg HospitalUniversity of New South WalesSingapore General HospitalSkånes universitetssjukhusErasmus Medisch CentrumThoracic Society of Australia and New ZealandModernaAllergy TherapeuticsAstraZenecaInsmedUniversity of AberdeenKing's College LondonMichael Smith Health Research BCCatholic University of KoreaCanadian Lung AssociationUniversity of TorontoMacquarie UniversityCollege of Medicine, Catholic University of KoreaShionogiHunter Medical Research InstituteUniversidad Nacional de RosarioAmerican Thoracic SocietyOptimum Patient CareHaukeland UniversitetssjukehusUniversiteit GentChiesi FarmaceuticiGlaxoSmithKlineCerecorPfizerUniversidad de Buenos AiresMonash UniversityUnited Therapeutics CorporationHorizon TherapeuticsNational Institute for Health and Care ResearchUniversity of QueenslandTaysWestern Sydney UniversityHáskóli ÍslandsLandspítali HáskólasjúkrahúsKindai UniversityNational and Kapodistrian University of AthensSeoul St. Mary's Hospital, Catholic University of KoreaKanazawa UniversityUCB PharmaCystic Fibrosis FoundationMylanInstituto de Seguriidad y Servicios Sociales de los Trabadores del EstadoCanadian Thoracic SocietyRegeneron PharmaceuticalsUniversitair Ziekenhuis GentGovernment of OntarioHumanitas UniversityUniwersytet ŁódzkiHelsingin YliopistoUniversité LavalSeqirusBristol-Myers SquibbEuropean Respiratory SocietySanofiCSL BehringGlenmark PharmaceuticalsDanoneGilead SciencesCelltrion HealthcareUniversità degli Studi di TorinoCovis PharmaUniversity of British ColumbiaEli Lilly and CompanyCelltrionIncyteCurtin University of TechnologyTaipei Veterans General HospitalAmgen
Mots-clésMedicineAsthmaBiomarkerCorticosteroidDiseaseIntensive care medicinePediatricsInternal medicine

Résumé

récupéré en direct d'OpenAlex

Background: Asthma characterization using blood eosinophil count (BEC) (among other biomarkers and clinical indices) is recommended in severe asthma (SA), but the masking effect of oral corticosteroids (OCS), makes this challenging. Aim: Our aim was to explore the effect of OCS use (both intermittent [iOCS] and long-term [LTOCS]) prior to biologic initiation on SA phenotype and biomarker profile in real-life and to characterize the burden of SA among patients prescribed LTOCS by biomarker profile. Methods: This was a registry-based cohort study, including data from 23 countries collected between 2003 and 2023 and shared with the Internatonal Severe Asthma Registry (ISAR). Patients with SA were categorized into 3 cohorts, those with: (i) no prescription for OCS, (ii) prescription(s) for iOCS (ie, ≤90 days in previous 12-months, usually short courses for exacerbations), and (iii) prescriptions for LTOCS (ie, >90 days in previous 12-months). Biomarker distribution (ie, BEC, fractional exhaled nitric oxide [FeNO], and total Immunoglobulin E [IgE]) were quantified in the year prior to biologic initiation in patients with SA according to OCS prescription pattern. Phenotypes were characterized for those prescribed LTOCS according to BEC cut-off (<150 and ≥ 150 cells/μL). Results: Of 4305 patients included, 5.0% (n = 215), 54.1% (n = 2330) and 40.9% (n = 1760) were prescribed no OCS, iOCS, and LTOCS, respectively. The BEC distribution varied by prescription pattern and LTOCS dose (<5 mg to ≥20 mg/day); BEC was <150 cells/μL in 28.6% (n = 369/1288) of LTOCS patients, compared to 19.5% (n = 284/1460) of iOCS patients and 14.0% (n = 21/150) of those in the no OCS group. Median BEC was also significantly lower in the LTOCS versus the iOCS group (310 vs 400 cells/μL; p < 0.001). A similar pattern was noted for IgE, but not FeNO. Among LTOCS patients with BEC <150 cells/μL, 39.9% experienced ≥4 exacerbations, 75.1% had uncontrolled asthma symptoms and 55.9% had evidence of persistent airflow obstruction (compared with 40.9%, 76.2% and 59.5% of those with BEC ≥150 cells/μL, respectively). Conclusions: OCS, whether prescribed intermittently or long term, affect BEC distribution potentially leading to heightened risk of phenotype misclassification and influencing subsequent treatment decisions. FeNO appears to be less susceptible to OCS-induced suppression. Disease burden was high for those in the LTOCS group and was high independent of dose and BEC. Our findings highlight the importance of considering OCS use, even intermittent use, when characterizing SA, and suggests the need for earlier phenotyping and alternative treatment strategies for LTOCS patients with low BEC.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,001
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,003
Score d'incertitude au seuil0,471

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0000,001
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,001
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,012
Tête enseignante GPT0,243
Écart entre enseignants0,231 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle